Abstracts tagged "marijuana"

Abstract Number: 879 • 2019 ACR/ARP Annual Meeting
Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
Heather Goodwin ¹, Ali Porter¹, Melinda Edwards ¹ and Bonita Libman ¹, ¹The University of Vermont Medical Center, Burlington, VT
Background/Purpose: To evaluate use of marijuana (MJ) and cannabidiol (CBD) as described by rheumatology patients at an academic medical center in Vermont, and to describe beliefs and…
Abstract Number: 2248 • 2019 ACR/ARP Annual Meeting
Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease
Kelly Gavigan¹, Shilpa Venkatachalam ¹, Jeffrey Curtis ², Carole Wiedmeyer ¹, Tien Sydnor-Campbell ¹, Christine Stake ¹, Terri Robinson ¹ and W. Benjamin Nowell ¹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: While there have been significant improvements in quality of life among people living with rheumatic and musculoskeletal disease (RMD) with the introduction of biologics…
Abstract Number: 2929 • 2019 ACR/ARP Annual Meeting
Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
Kristin Wipfler ¹, Teresa Simon², Patricia Katz ³, Frederick Wolfe ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³University of California, San Francisco, san francisco, CA, ⁴FORWARD, The National Databank for Rheumatic Diseases & University of Nebraska Medical Center, Wichita, KS, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results…
Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Tara Landry¹, Mary-Ann Fitzcharles², Peter A. Ste-Marie³ and Yoram Shir³, ¹Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, ²Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].